Category: Intellectual property
-
Spin-Off Producing Commercial-Grade Graphene
A company based on university lab research in the U.K. says it’s producing graphene, a promising carbon-based material, in quality and scale for electronics.
-
Start-Up Creating Touch Sensing for Visual Images
A start-up company spun off from Purdue University is developing a system that translates visual images to touch-sensing signals for people with limited visual abilities.
-
Start-Up Raises $10.5M for Precision Immunotherapies
A new biotechnology enterprise developing personalized treatments that harness the immune system to treat cancer is raising $10.5 million in its first venture funding round.
-
MIT Spins-Off 32 Start-Ups in 2018
Research done at Massachusetts Institute of Technology in 2018 led to creation of 32 new start-up enterprises as well as hundreds of licenses and patents.
-
UC-Berkeley to Get New Crispr Patent
University of California in Berkeley will soon receive a new patent for its development of the genome editing process known as Crispr, the latest round in a years-long dispute.
-
Company to Stop Cancer Spread, Relapse Raises $60.8M
A new company formed to commercialize research that aims to prevent cancer from spreading or recurring is raising $60.75 million in its first venture financing.
-
Lilly, Biopharm Partner on Alzheimer’s Treatment in $2B Deal
Eli Lilly and Co. is licensing a a treatment candidate for Alzheimer’s disease from biopharmaceutical company AC Immune that aims to block accumulation of tau proteins in the brain.
-
Patent Set for Long-Term Drug Capsules
Techniques for delivering drugs in capsule form that last a week or longer in the patient are expected to receive a patent soon from U.S. authorities.
-
Janssen Licensing Cancer Antibodies in $1.8B Deal
An affiliate of drug maker Janssen Pharmaceutical is licensing a synthetic antibody to treat blood-related cancers from a developer of antibodies based on the immune system of llamas.
-
Gene Silencing Technology Licensed in $3.7B Deal
Dicerna Pharmaceuticals, developing treatments for disease that silence genes by interfering with their RNA instructions, is licensing its technology to drug maker Eli Lilly and Co